Mird-226 Access

Provide standardized dosimetry methods and guidance for calculating absorbed doses in diagnostic and therapeutic nuclear medicine procedures involving [specific radiopharmaceutical or modality — insert if known]. (Assumed goal based on MIRD series purpose: harmonize dose calculation, improve consistency and accuracy.)

The Medical Imaging and Radiation Therapy (MIRT) committee, through its various pamphlets and publications, provides critical guidance on the safe and effective use of radiopharmaceuticals in both diagnostic and therapeutic settings. These publications serve as a cornerstone for education and practice guidelines for professionals in nuclear medicine and molecular imaging.

Publications from the MIRD committee, such as pamphlets or reports (including potentially MIRD-226), typically cover a range of topics related to radiation dosimetry. These might include: MIRD-226

¹³¹I is a beta emitter with a physical half-life of approximately 8 days. It is selectively taken up by the thyroid gland, where it destroys thyroid tissue. This selective uptake makes ¹³¹I an ideal therapeutic agent for thyroid diseases, offering a targeted approach to treatment with minimal impact on surrounding tissues.